Compare VENUS REMEDIES with Sterling Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs STERLING BIOTECH - Comparison Results

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES STERLING BIOTECH VENUS REMEDIES/
STERLING BIOTECH
 
P/E (TTM) x -15.9 -0.4 - View Chart
P/BV x 1.1 0.0 7,449.4% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 VENUS REMEDIES   STERLING BIOTECH
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
STERLING BIOTECH
Dec-13
VENUS REMEDIES/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs12611 1,199.0%   
Low Rs613 1,797.1%   
Sales per share (Unadj.) Rs301.826.8 1,125.8%  
Earnings per share (Unadj.) Rs-24.9-15.0 166.3%  
Cash flow per share (Unadj.) Rs2.5-5.5 -46.6%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs293.354.9 534.4%  
Shares outstanding (eoy) m12.34267.87 4.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.30.3 119.5%   
Avg P/E ratio x-3.8-0.5 809.1%  
P/CF ratio (eoy) x36.7-1.3 -2,888.2%  
Price / Book Value ratio x0.30.1 251.8%  
Dividend payout %00-   
Avg Mkt Cap Rs m1,1541,862 62.0%   
No. of employees `0000.91.4 68.3%   
Total wages/salary Rs m393547 71.9%   
Avg. sales/employee Rs Th4,026.15,303.3 75.9%   
Avg. wages/employee Rs Th425.0403.8 105.2%   
Avg. net profit/employee Rs Th-331.8-2,959.0 11.2%   
INCOME DATA
Net Sales Rs m3,7247,181 51.9%  
Other income Rs m2343 52.8%   
Total revenues Rs m3,7477,223 51.9%   
Gross profit Rs m395947 41.7%  
Depreciation Rs m3382,543 13.3%   
Interest Rs m3544,377 8.1%   
Profit before tax Rs m-275-5,931 4.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m32-1,924 -1.6%   
Profit after tax Rs m-307-4,007 7.7%  
Gross profit margin %10.613.2 80.4%  
Effective tax rate %-11.532.4 -35.4%   
Net profit margin %-8.2-55.8 14.8%  
BALANCE SHEET DATA
Current assets Rs m2,63814,335 18.4%   
Current liabilities Rs m2,30549,809 4.6%   
Net working cap to sales %8.9-494.0 -1.8%  
Current ratio x1.10.3 397.7%  
Inventory Days Days135403 33.6%  
Debtors Days Days46171 27.1%  
Net fixed assets Rs m4,87155,432 8.8%   
Share capital Rs m123268 46.1%   
"Free" reserves Rs m3,49613,935 25.1%   
Net worth Rs m3,61914,701 24.6%   
Long term debt Rs m1,3749,478 14.5%   
Total assets Rs m7,50973,988 10.1%  
Interest coverage x0.2-0.4 -62.8%   
Debt to equity ratio x0.40.6 58.9%  
Sales to assets ratio x0.50.1 511.1%   
Return on assets %0.60.5 126.0%  
Return on equity %-8.5-27.3 31.1%  
Return on capital %1.6-6.4 -24.6%  
Exports to sales %025.9 0.0%   
Imports to sales %13.90.2 8,163.7%   
Exports (fob) Rs mNA1,860 0.0%   
Imports (cif) Rs m51712 4,233.9%   
Fx inflow Rs m01,860 0.0%   
Fx outflow Rs m51725 2,075.1%   
Net fx Rs m-5171,835 -28.1%   
CASH FLOW
From Operations Rs m5141,719 29.9%  
From Investments Rs m-123-3,148 3.9%  
From Financial Activity Rs m-3871,426 -27.1%  
Net Cashflow Rs m4-3 -123.5%  

Share Holding

Indian Promoters % 32.9 33.9 96.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 0.0 -  
FIIs % 0.6 9.9 5.9%  
ADR/GDR % 0.0 16.9 -  
Free float % 66.4 39.3 169.0%  
Shareholders   20,121 21,482 93.7%  
Pledged promoter(s) holding % 36.4 55.9 65.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   SHASUN PHARMA  WYETH  TORRENT PHARMA  ALEMBIC  DR. REDDYS LAB  

Compare VENUS REMEDIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Recover From Day's Low to End Strong; JSW Steel and ICICI Bank Among Top Nifty Gainers(Closing)

Indian share markets recouped early losses during afternoon deals and ended today's volatile session higher.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

Top 3 Nifty ETFs to Buy Now(Fast Profits Daily)

Apr 20, 2021

In this video I tell you the three Nifty ETFs I think are the best.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

11x Bankruptcy to Bluechip Stock: A Rare India Revival Story(Profit Hunter)

Apr 16, 2021

There is no stopping this 11-bagger stock from significant upside.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Apr 22, 2021 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 5-YR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS